sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe
Company profile
Ticker
PCVX
Exchange
Website
CEO
Grant Pickering
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SutroVax, Inc.
SEC CIK
Corporate docs
Subsidiaries
Vaxcyte Switzerland GmbH ...
IRS number
464233385
PCVX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
424B5
Prospectus supplement for primary offering
31 Jan 24
8-K
Other Events
31 Jan 24
424B5
Prospectus supplement for primary offering
30 Jan 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
Latest ownership filings
4
Mikhail Eydelman
3 Apr 24
4
Jim Wassil
3 Apr 24
4
GRANT PICKERING
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
GRANT PICKERING
27 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
4
ANDREW GUGGENHIME
20 Mar 24
4
Jim Wassil
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm |
Cash burn (monthly) | (no burn) | (no burn) | 37.68 mm | 29.83 mm | 19.18 mm | 19.43 mm |
Cash used (since last report) | n/a | n/a | 249.37 mm | 197.43 mm | 126.97 mm | 128.63 mm |
Cash remaining | n/a | n/a | 296.87 mm | 348.81 mm | 419.27 mm | 417.61 mm |
Runway (months of cash) | n/a | n/a | 7.9 | 11.7 | 21.9 | 21.5 |
Institutional ownership, Q3 2023
99.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 201 |
Opened positions | 22 |
Closed positions | 23 |
Increased positions | 85 |
Reduced positions | 57 |
13F shares | Current |
---|---|
Total value | 5.10 tn |
Total shares | 107.59 mm |
Total puts | 41.10 k |
Total calls | 49.60 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
FMR | 14.08 mm | $717.65 bn |
Vanguard | 8.28 mm | $422.33 bn |
Ra Capital Management | 7.89 mm | $402.30 bn |
BLK Blackrock | 7.42 mm | $378.34 bn |
JHG Janus Henderson | 7.06 mm | $359.91 bn |
Wellington Management | 4.60 mm | $234.44 bn |
Capital Research Global Investors | 3.36 mm | $171.50 bn |
STT State Street | 3.15 mm | $160.35 bn |
Longitude Capital Partners II | 3.11 mm | $82.54 mm |
T. Rowe Price | 2.42 mm | $122.55 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 68.1 | 3 | 204.30 | 147,362 |
1 Apr 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 67.244 | 415 | 27.91 k | 147,365 |
1 Apr 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 66.447 | 890 | 59.14 k | 147,780 |
1 Apr 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 67.273 | 324 | 21.80 k | 147,362 |
1 Apr 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 66.521 | 984 | 65.46 k | 147,686 |
1 Apr 24 | Jim Wassil | Common Stock | Sell | Dispose S | No | Yes | 67.229 | 677 | 45.51 k | 218,289 |
1 Apr 24 | Jim Wassil | Common Stock | Sell | Dispose S | No | Yes | 66.531 | 2,323 | 154.55 k | 218,966 |
1 Apr 24 | Mikhail Eydelman | Common Stock | Sell | Dispose S | No | Yes | 67.416 | 270 | 18.20 k | 30,597 |
1 Apr 24 | Mikhail Eydelman | Common Stock | Sell | Dispose S | No | Yes | 66.594 | 1,397 | 93.03 k | 30,867 |
1 Apr 24 | Mikhail Eydelman | Common Stock | Option exercise | Acquire M | No | No | 21.41 | 1,667 | 35.69 k | 32,264 |
News
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
10 Apr 24
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
10 Apr 24
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
12 Mar 24
Mizuho Maintains Buy on Vaxcyte, Raises Price Target to $113
12 Mar 24
Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
4 Mar 24
Press releases
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2 Feb 24
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
1 Feb 24
Vaxcyte Announces Pricing of $750 Million Public Offering
30 Jan 24